S A Hebisha1, H M Adel1. 1. Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Abstract
OBJECTIVE: To study the effect of GnRh agonist administration prior to estrogen-progesterone preparation of the endometrium on the implantation rate in frozen-thawed embryo transfer (FET) cycles in infertile patients treated withIVF/ICSI. DESIGN: Prospective controlled study. SETTING:Private center in Alexandria, Egypt. PATIENTS: Patients undergoing frozen-thawed embryo transfer FET. INTERVENTIONS: Patients were divided into two groups, A and B. Group A patients consisted of 110 patients (110 cycles) who received daily subcutaneous injections of 0.1 mg of the GnRh agonist triptorelin starting from the mid-luteal phase of the cycle preceding the actual FET cycle. The dose was reduced to 0.05 mg from the second day of the cycle when daily oral estradiol valerate 6 mg was also started. Daily vaginal supplementation of micronized progesterone 400 mg b.d. was started after 12 days when the GnRh agonist was also stopped. Frozen-thawed embryos were transferred on day + 1 of their chronological age and when the endometrium reached 12 mm in thickness. Group B consisted of 100 patients (100 cycles) whostarted daily estradiol valerate 6 mg administration from the second day of the FET cycle and followed the same regimen but without prior treatment with triptorelin. MAIN OUTCOME MEASURES: Implantation and pregnancy rates were compared among the two groups. RESULTS: There was a significant increase in implantation rate in the GnRh agonist group (group A) compared to the estrogen and progesterone only group (group B) (44.1 vs. 21.1 %; P = 0.002*). The pregnancy rate was also significantly higher in group A compared to group B (65.5 vs. 42 %, P = 0.013*). CONCLUSIONS: GnRh agonist administration during endometrial preparation for FET increases the implantation and pregnancy rates.
RCT Entities:
OBJECTIVE: To study the effect of GnRh agonist administration prior to estrogen-progesterone preparation of the endometrium on the implantation rate in frozen-thawed embryo transfer (FET) cycles in infertilepatients treated with IVF/ICSI. DESIGN: Prospective controlled study. SETTING: Private center in Alexandria, Egypt. PATIENTS: Patients undergoing frozen-thawed embryo transfer FET. INTERVENTIONS:Patients were divided into two groups, A and B. Group A patients consisted of 110 patients (110 cycles) who received daily subcutaneous injections of 0.1 mg of the GnRh agonist triptorelin starting from the mid-luteal phase of the cycle preceding the actual FET cycle. The dose was reduced to 0.05 mg from the second day of the cycle when daily oral estradiol valerate 6 mg was also started. Daily vaginal supplementation of micronized progesterone 400 mg b.d. was started after 12 days when the GnRh agonist was also stopped. Frozen-thawed embryos were transferred on day + 1 of their chronological age and when the endometrium reached 12 mm in thickness. Group B consisted of 100 patients (100 cycles) who started daily estradiol valerate 6 mg administration from the second day of the FET cycle and followed the same regimen but without prior treatment with triptorelin. MAIN OUTCOME MEASURES: Implantation and pregnancy rates were compared among the two groups. RESULTS: There was a significant increase in implantation rate in the GnRh agonist group (group A) compared to the estrogen and progesterone only group (group B) (44.1 vs. 21.1 %; P = 0.002*). The pregnancy rate was also significantly higher in group A compared to group B (65.5 vs. 42 %, P = 0.013*). CONCLUSIONS: GnRh agonist administration during endometrial preparation for FET increases the implantation and pregnancy rates.
Authors: Tarek A Gelbaya; Luciano G Nardo; Helen R Hunter; Cheryl T Fitzgerald; Greg Horne; Elizabeth E H Pease; Daniel R Brison; Brian A Lieberman Journal: Fertil Steril Date: 2006-03 Impact factor: 7.329
Authors: Kalliopi E Loutradi; Efstratios M Kolibianakis; Christos A Venetis; Evangelos G Papanikolaou; George Pados; Ioannis Bontis; Basil C Tarlatzis Journal: Fertil Steril Date: 2007-11-05 Impact factor: 7.329